A
AstraZeneca
AstraZeneca and Handa Pharmaceuticals settled for $5.475 million over antitrust claims related to Seroquel XR generic medications.
ClosedSelected statesClaim status: Closed on June 9, 2025Payout: VariesNo longer claimable
About this settlement
Antitrust settlement for delayed generic competition on Seroquel XR extended-release tablets.
This settlement resolves claims that AstraZeneca and Handa Pharmaceuticals violated antitrust laws by delaying the market entry of generic Seroquel XR medications. Eligible third-party payors who purchased or reimbursed for Seroquel XR or generic quetiapine fumarate ER tablets may submit claims for compensation.
Who qualifies
- Third-party payors who purchased, paid for, or reimbursed Seroquel XR or generic quetiapine fumarate ER tablets.
- Purchases made between September 5, 2015 and December 9, 2024.
- Residents or entities in specified U.S. states and the District of Columbia.
Varies
Claim status: Closed on June 9, 2025